文献速递冠心病

定量冠状动脉造影与血管内超声指导药物洗脱支架植入的随机临床试验

Quantitative Coronary Angiography vs Intravascular Ultrasonography to Guide Drug-Eluting Stent Implantation: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2024-01-01

该随机、开放标签、非劣效性试验在韩国6个心脏中心纳入1528例需PCI的冠心病患者,比较QCA与IVUS指导支架植入的12个月靶病变失败率。结果显示QCA组3.81%与IVUS组3.80%相似(绝对风险差0.01个百分点,95%CI -1.91至1.93),但因事件率低于预期需谨慎解读。

要点

  • QCA指导PCI的12个月靶病变失败率与IVUS指导相似,绝对风险差0.01个百分点。
  • 支架边缘夹层、冠状动脉穿孔和支架血栓发生率两组间无差异。
  • 因事件率低于预期,非劣效性结论需谨慎解读。

核心结论

  • QCA与IVUS指导PCI在12个月靶病变失败率上相似。
  • 因事件率低于预期, findings应谨慎解读。

研究设计与样本

  • 随机、开放标签、非劣效性临床试验,在韩国6个心脏中心进行。
  • 纳入1528例成人冠心病患者,1:1随机接受QCA或IVUS指导PCI。
  • 主要分析按意向治疗原则进行。

主要发现

  • 12个月靶病变失败在QCA组29/763例(3.81%),IVUS组29/765例(3.80%)。
  • 亚组分析中主要终点风险一致,无显著交互作用。

关键数值与推荐

  • 主要终点为12个月靶病变失败,定义为心性死亡、靶血管心肌梗死或缺血驱动的靶病变血运重建的复合终点。
  • 非劣效性界值为12个月靶病变失败绝对差(QCA减IVUS)的单侧97.5%CI上限小于3.5个百分点。
  • 试验设计假设事件率为8%。

临床怎么用

  • 在无法使用IVUS的导管室,QCA指导PCI可作为替代策略。
  • QCA指导PCI未增加支架边缘夹层、穿孔或支架血栓风险。

局限性

  • 试验中靶病变失败事件率低于预期,可能影响非劣效性结论的稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although intravascular ultrasonography (IVUS) guidance promotes favorable outcomes after percutaneous coronary intervention (PCI), many catheterization laboratories worldwide lack access. OBJECTIVE: To investigate whether systematic implementation of quantitative coronary angiography (QCA) to assist angiography-guided PCI could be an alternative strategy to IVUS guidance during stent implantation. DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, noninferiority clinical trial enrolled adults (aged ≥18 years) with chronic or acute coronary syndrome and angiographically confirmed native coronary artery stenosis requiring PCI. Patients were enrolled in 6 cardiac centers in Korea from February 23, 2017, to August 23, 2021, and follow-up occurred through August 25, 2022. All principal analyses were performed according to the intention-to-treat principle. INTERVENTIONS: After successful guidewire crossing of the first target lesion, patients were randomized in a 1:1 ratio to receive either QCA- or IVUS-guided PCI. MAIN OUTCOMES AND MEASURES: The primary outcome was target lesion failure at 12 months, defined as a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. The trial was designed assuming an event rate of 8%, with the upper limit of the 1-sided 97.5% CI of the absolute difference in 12-month target lesion failure (QCA-guided PCI minus IVUS-guided PCI) to be less than 3.5 percentage points for noninferiority. RESULTS: The trial included 1528 patients who underwent PCI with QCA guidance (763; mean [SD] age, 64.1 [9.9] years; 574 males [75.2%]) or IVUS guidance (765; mean [SD] age, 64.6 [9.5] years; 622 males [81.3%]). The post-PCI mean (SD) minimum lumen diameter was similar between the QCA- and IVUS-guided PCI groups (2.57 [0.55] vs 2.60 [0.58] mm, P = .26). Target lesion failure at 12 months occurred in 29 of 763 patients (3.81%) in the QCA-guided PCI group and 29 of 765 patients (3.80%) in the IVUS-guided PCI group (absolute risk difference, 0.01 percentage points [95% CI, -1.91 to 1.93 percentage points]; hazard ratio, 1.00 [95% CI, 0.60-1.68]; P = .99). There was no difference in the rates of stent edge dissection (1.2% vs 0.7%, P = .25), coronary perforation (0.2% vs 0.4%, P = .41), or stent thrombosis (0.53% vs 0.66%, P = .74) between the QCA- and IVUS-guided PCI groups. The risk of the primary end point was consistent regardless of subgroup, with no significant interaction. CONCLUSIONS AND RELEVANCE: Findings of this randomized clinical trial indicate that QCA and IVUS guidance during PCI showed similar rates of target lesion failure at 12 months. However, due to the lower-than-expected rates of target lesion failure in this trial, the findings should be interpreted with caution. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02978456.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Lee, Hong, Kim, et al. Quantitative Coronary Angiography vs Intravascular Ultrasonography to Guide Drug-Eluting Stent Implantation: A Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 38477913. doi:10.1001/jamacardio.2024.0059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。